Researchers found that the combination therapy improved progression-free survival across various sub-groups, including those with poor prognostic factors. The study also showed similar efficacy regardless of BRAF mutation status and disease stage.
Researchers found molecular differences in younger-onset CRC tumors related to epigenetics and gene expression. This discovery could lead to tailored treatments for younger patients. The study analyzed genetic mutations in 126 under-50 patients and 368 over-50 patients, revealing distinctive patterns.
The study found substantial differences in surgery, hormone therapy, and chemotherapy use among European countries for elderly breast cancer patients. Treatment approaches varied depending on the stage of the disease, with some countries omitting surgery or using more chemotherapy than others.
A new report highlights progress in treating childhood cancers, but notes that many survivors face long-term treatment-related side effects. The European Society for Paediatric Oncology proposes solutions to tackle these issues, including improving access to new drugs and enhancing collaboration with adult oncology.
Researchers found that brain metastases share some genetic similarities with the primary tumor but also have key differences, including potential drug targets in over half of patients. Genetic analysis of brain metastases could reveal new treatment options, especially when compared to primary tumors.
Researchers have shown that the mTOR inhibitor everolimus can delay tumour growth among both gastrointestinal and lung NETs, particularly for patients with lung tumours. The trial included 302 patients and found a 52% reduction in progression or death risk and a clinically meaningful improvement in median progression-free survival.
A phase III trial has shown that 177Lu-DOTATATE significantly improves progression-free survival in patients with mid-gut neuroendocrine tumours, a rare and hard-to-treat disease. The treatment outperforms standard care in terms of time without disease progression.
The CheckMate 025 phase III clinical trial shows that nivolumab significantly prolongs survival in patients with advanced kidney cancer, regardless of PD-L1 expression. The study found a median overall survival of 25 months for nivolumab-treated patients compared to 19.6 months for those treated with everolimus.
The EUROCARE 5 study shows significant geographical variations in survival from blood cancers in Europe, with the highest five-year relative survival rate for Hodgkin lymphoma at 81% in Northern European countries. In contrast, chronic myeloid leukemia had a significantly lower survival rate of 53%, particularly in Eastern Europe.
Patients with advanced throat cancer who underwent primary surgery had significantly higher overall survival rates compared to those who did not. The study found that radical surgery improved survival in both oropharyngeal and hypopharyngeal cancers, with notable benefits for patients with stage III and IVa disease.
Results from the METEOR trial show that cabozantinib improves progression-free and overall survival in patients with advanced clear cell kidney cancer, with a median progression-free survival of 7.4 months compared to 3.8 months for everolimus.
A study of 1,000 breast cancer patients found genetic differences between primary tumours and recurring cancers. The research identified potential targets for new therapies, including JAK inhibitors, to prevent cancer recurrence.
A phase I clinical trial has demonstrated that ASP8273 causes tumour shrinkage in patients with treatment-resistant non-small cell lung cancer (NSCLC) who have both the EGFR and T790M mutations. The overall response rate is 78%, comparable to other drugs in development.
A multi-centre clinical trial suggests that a combination of three targeted drugs may be more effective than one drug for certain patients with advanced BRAF-mutated colorectal cancer. The treatment, which includes encorafenib, cetuximab, and alpelisib, showed improved efficacy and extended progression-free survival in patients.
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumors have responded to the new drug E7438, a histone methyltransferase inhibitor. The drug has shown anti-tumor effects in four patients with refractory lymphoma and one patient with a malignant rhabdoid tumor, indicating potential for personalized medical therapy.
Scientists have found a biological indicator that can predict which women without BRCA1/2 mutations will respond well to the PARP inhibitor rucaparib. The biomarker is related to genomic loss of heterozygosity, and its presence indicates that patients with ovarian cancers may benefit from treatment.
Researchers have successfully treated cervical cancer patients with a combination of cidofovir and chemoradiation without increased toxic side effects. The treatment resulted in tumour shrinkage and complete response in 80% of patients, making it a promising new approach for HPV-related cancers.
A phase I trial of AG-120, an oral inhibitor of mutant IDH1, has shown clinical activity in patients with advanced acute myeloid leukaemia (AML) and the IDH1 mutation. The drug reduced 2-HG levels to normal, allowing cells to mature into normal functioning cells.
Patients with advanced papillary kidney cancer respond well to a combination of bevacizumab and erlotinib, with excellent response rates and long-lasting results. The treatment shows promise for patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have poor prognosis.
Researchers found galeterone to be effective in lowering PSA levels and stabilizing disease in patients with CRPC. The drug showed promising activity against the AR-V7 variant, a mechanism of resistance in this disease.
A phase I/II clinical trial has demonstrated that rociletinib, a new oral EGFR inhibitor, can respond to treatment-resistant advanced non-small cell lung cancer, including those with the T790M resistance mutation. The overall response rate was 46%, and disease control rate was 84% among patients who received the pivotal dose.
Research from The Netherlands found that extending national breast cancer screening programs to women aged 70 and over does not decrease advanced stage cancer detection, but rather increases early-stage tumors. This leads to a large proportion of women being over-treated and at risk from the harmful effects of treatment.
A UK NHS Breast Screening Programme audit found significant variations in treatment for women with ductal carcinoma in situ (DCIS), resulting in adverse outcomes. The study revealed that some hospitals performed mastectomies on women who should have had lumpectomy, highlighting the need to improve multidisciplinary team discussions.
A UK study found that approximately one third of women are at higher risk of developing breast cancer and may require more frequent mammograms. Women with dense breast tissue were 2.9-fold more likely to develop breast cancer, highlighting the importance of personalized screening frequency.
Research finds that obese patients have a higher risk of cancer recurrence and metastasis after neoadjuvant chemotherapy. Diabetes also affects cancer outcomes, particularly in hormone receptor-positive tumours, increasing the risk of death from all causes by 49%.
A meta-analysis of 37 studies found that regular physical activity reduces breast cancer risk by 12% compared to the least active women. The protective effect of exercise seems to be cancelled out in women taking hormone replacement therapy, but this trend may change as HRT use decreases.
Breast cancer mortality rates in Europe have decreased from 1989 to 2010 due to improved treatments and enhanced access to care. However, notable variations between countries remain, with France showing a modest decrease despite devoting substantial resources to cancer care.
Breast cancer is a significant global health issue, with over 1.6 million new cases diagnosed annually. The disease disproportionately affects low-income countries, where late-stage diagnosis and limited treatment options contribute to high mortality rates.
New research finds that radiotherapy after mastectomy reduces recurrence and death rates for women with early breast cancer in 1-3 positive lymph nodes. The study, which analyzed data from 3786 women, shows a significant benefit of radiotherapy regardless of chemotherapy or hormonal therapy use.
Researchers have identified genetic markers that can predict late recurrence of ER+ breast cancer, allowing for personalized treatment decisions. Women with tumours highly sensitive to oestrogen may benefit from extended hormone therapy beyond five years.
A pilot study reveals large variations in patient survival rates after surgery for oesophageal and gastric cancers across European countries. The new European Upper GI Cancer Audit aims to identify key factors contributing to these differences.
A new report from ECCO highlights the growing burden of cancer worldwide, with India, China, and Nigeria expected to see dramatic increases in cases due to population growth and lifestyle changes. The report calls for a major public-private partnership to improve cancer care and outcomes globally.
Researchers estimated that approximately 0.60 Gray of the daily radiotherapy dose is 'wasted' due to overnight and weekend tumor growth, suggesting shorter treatment schedules may be more effective against breast cancer recurrence. This finding supports current trends to deliver shorter radiotherapy schedules.
Researchers discovered that aspirin improves survival in patients with colon cancer whose tumour cells express Human Leukocyte Antigen class I (HLA class I), a cell-surface protein involved in the immune system. The study found that HLA class I could be used to predict which patients benefit from aspirin therapy.
A clinical trial suggests that combining radiotherapy with an anti-cancer drug called APG101 blocks a cell-signalling pathway crucial for glioblastoma development. The treatment showed promising results, with patients receiving the combination therapy living longer than those treated with radiotherapy alone.
A clinical trial found that cediranib, a biological therapy, extended the time before ovarian cancer recurred and increased overall survival by up to 30% compared to chemotherapy alone. The treatment showed incremental improvements in progression-free and overall survival.
Researchers have identified molecular profiles of tumors with unknown primary sites, allowing for more effective treatment and improved survival rates. The study found that the biology of the tumor is more important than its primary site in determining treatment effectiveness.
Researchers estimate that routine PSA testing can lead to increased impotence and incontinence cases, as well as additional prostate cancer diagnoses. However, the difference in death rates between screened and unscreened men is relatively small, with only 0.07 more deaths attributed to screening.
A phase I clinical trial has shown that an anti-PD-L1 monoclonal antibody can produce striking responses in non-small cell lung cancer patients with metastatic disease who have failed to respond to previous chemotherapy. Smokers and former smokers are more likely to benefit from this treatment.
A meta-analysis of over 11,000 patients showed that hyperfractionated radiotherapy (AFRT) reduces the risk of death by 8% compared to standard fractionation radiotherapy (SFRT). AFRT also improves locoregional control, with a significant increase in five-year survival rates.
The TH3RESA trial shows that T-DM1 significantly improves progression-free survival in women with advanced HER2 positive breast cancer, with a nearly three-month increase from 3.3 months to 6.2 months. The treatment also demonstrates a more favorable safety profile compared to standard therapy.
Research finds that increased government spending on health care is associated with decreased cancer mortality rates in Europe. Eastern European countries tend to have higher mortality rates, while Western Europe has better outcomes due to effective screening programs and treatments.
A meta-analysis found that diabetic patients have an increased risk of developing both breast and colon cancer. The study also showed that diabetic patients are at a higher risk of dying from these cancers, with a 23% increased risk for breast cancer and a 38% increased risk for colon cancer compared to non-diabetic patients.
The Phase II study showed that everolimus successfully slowed or prevented disease spread in 59% of patients. Everolimus may represent a new treatment option for advanced papillary kidney cancer, which accounts for 15% of all kidney cancer cases.
A new study has found that treating chest lymph nodes in early breast cancer patients improves overall survival without increasing side effects. The research involved 4004 patients from 43 centres and found that irradiating the IM-MS lymph nodes gave a better patient outcome than radiation therapy to the breast/thoracic wall alone.
A recent study found that colorectal cancer screening programs in European countries have a significant impact on reducing mortality rates. The researchers analyzed data from 11 European countries and found that the scope and take-up of CRC screening activities were strongly related to the reductions in death rates.
A study of 4846 patients treated with ipilimumab reveals that some can survive for up to 10 years, with a plateau in overall survival starting around three years. This finding provides valuable insight into the long-term efficacy of the treatment and its potential as a benchmark for future medicines.
A large-scale analysis of 20,034 patients found that young age is associated with worse overall survival and progression-free survival in those with metastatic colorectal cancer. The study suggests that these patients have a poorer prognosis if their disease has metastasized.
The SHIVA trial is the first randomised trial to look at patient outcomes after treatments were chosen according to individual molecular profiles. Preliminary results show that this approach works, paving the way for personalized treatment and a potential major change in cancer drug development.
A phase III clinical trial found that the combination of everolimus and exemestane improved bone strength and reduced the chance of cancer spreading in the bone. The treatment also showed a lower rate of further tumour growth and more difficult metastases to occur.